Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cortexyme Inc (NQ: CRTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cortexyme Inc < Previous 1 2 3 4 5 Next > Stocks That Hit 52-Week Lows On Thursday July 28, 2022 On Thursday, 108 companies set new 52-week lows. Via Benzinga Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves May 03, 2022 Via Benzinga Recap of Wednesday's Biotech Catalysts - End of The Day Summary July 27, 2022 Via Benzinga Stocks That Hit 52-Week Lows On Wednesday July 27, 2022 Wednesday saw 83 companies set new 52-week lows. Via Benzinga Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 July 27, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 July 27, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections June 21, 2022 From Cortexyme, Inc. Via Business Wire Stocks That Hit 52-Week Lows On Monday July 25, 2022 On Monday, 100 companies reached new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Friday June 24, 2022 On Friday, 61 companies hit new 52-week lows. Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session June 16, 2022 Gainers Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 34.4% to $2.81 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million. Via Benzinga Cortexyme Appoints June Bray to its Board of Directors June 13, 2022 From Cortexyme, Inc. Via Business Wire 69 Biggest Movers From Friday June 06, 2022 Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... Via Benzinga Stocks That Hit 52-Week Lows On Wednesday June 01, 2022 On Wednesday, 73 stocks hit new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Tuesday May 31, 2022 On Tuesday, 36 companies achieved new lows for the year. Via Benzinga Cortexyme Appoints Dr. Philip Low to Its Board of Directors May 20, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme Successfully Completes Acquisition of Novosteo May 20, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases May 12, 2022 From Cortexyme, Inc. Via Business Wire 103 Biggest Movers From Yesterday May 11, 2022 Gainers Via Benzinga 77 Stocks Moving In Tuesday's Mid-Day Session May 10, 2022 Gainers Via Benzinga The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves May 10, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Cortexyme Announces Agreement to Acquire Novosteo May 10, 2022 From Cortexyme, Inc. Via Business Wire The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs May 03, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc. April 29, 2022 San Diego, CA -- (SBWIRE) -- 04/29/2022 -- Certain directors of Cortexyme, Inc. are under investigation over potential breaches of fiduciary duties. Via SBWire ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX April 05, 2022 From The Rosen Law Firm, P.A. Via Business Wire Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population March 21, 2022 From Cortexyme, Inc. Via Business Wire Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today March 15, 2022 Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! Via InvestorPlace Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors March 15, 2022 From Cortexyme, Inc. Via Business Wire Cortexyme to Present New GAIN Trial Data at AD/PD 2022 March 14, 2022 From Cortexyme, Inc. Via Business Wire 10 Biggest Price Target Changes For Wednesday March 09, 2022 Telsey Advisory Group cut the price target on Stitch Fix, Inc. (NASDAQ: SFIX) from $25 to $14. Stitch Fix shares fell 24.5% to $8.31 in pre-market trading. Via Benzinga Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis March 08, 2022 Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection... Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.